Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer

Item

http://www.wikidata.org/entity/Q36147155

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Phase 1b dose-finding study of ...... with metastatic breast cancer

@ast

Phase 1b dose-finding study of ...... with metastatic breast cancer

@en

type

Item

label

Phase 1b dose-finding study of ...... with metastatic breast cancer

@ast

Phase 1b dose-finding study of ...... with metastatic breast cancer

@en

prefLabel

Phase 1b dose-finding study of ...... with metastatic breast cancer

@ast

Phase 1b dose-finding study of ...... with metastatic breast cancer

@en

P1476

Phase 1b dose-finding study of ...... with metastatic breast cancer

@en

P2093

Adeboye H Adewoye

http://www.w3.org/2001/XMLSchema#string

Arlene Chan

http://www.w3.org/2001/XMLSchema#string

Dusan Kotasek

http://www.w3.org/2001/XMLSchema#string

Paul Mainwaring

http://www.w3.org/2001/XMLSchema#string

Peter A Kaufman

http://www.w3.org/2001/XMLSchema#string

Rebeca Melara

http://www.w3.org/2001/XMLSchema#string

Richard H De Boer

http://www.w3.org/2001/XMLSchema#string

Robert Sikorski

http://www.w3.org/2001/XMLSchema#string

Shane White

http://www.w3.org/2001/XMLSchema#string

Yining Ye

http://www.w3.org/2001/XMLSchema#string

P2860

The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

P2888

s10549-012-2135-0

P304

241-252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-012-2135-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

135

http://www.w3.org/2001/XMLSchema#string

P50

Bogda Koczwara

P577

2012-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230633030

http://www.w3.org/2001/XMLSchema#string

P698

22872523

http://www.w3.org/2001/XMLSchema#string

P932

3413817

http://www.w3.org/2001/XMLSchema#string